XML 16 R9.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2024
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

The following provides information regarding Rule 10b5-1 trading arrangements (as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, each a "10b5-1 Plan") adopted in the third quarter of 2024 by any director or officer who is subject to the filing requirements of Section 16 of the Securities Exchange Act of 1934 ("Section 16 Director or Officer"):

Anish Bhatnagar, our Chief Executive Officer, President and Chief Operating Officer, and a member of our board of directors adopted a 10b5-1 Plan on September 6, 2024. Mr. Bhatnagar's 10b5-1 Plan provides for the potential sale of up to 300,000 shares of

our common stock, and expires on September 6, 2025, or upon the earlier completion of all authorized transactions thereunder. The first trade will not occur until January 15, 2025, at the earliest.

Jim Mackaness, our Chief Financial Officer, adopted a 10b5-1 Plan on September 6, 2024. Mr. Mackaness' 10b5-1 Plan provides for the potential sale of up to 60,000 shares of our common stock, and expires on September 6, 2025, or upon the earlier completion of all authorized transactions thereunder. The first trade will not occur until January 15, 2025, at the earliest.

Patricia C. Hirano, our Senior Vice President, Regulatory Affairs, adopted a 10b5-1 Plan on September 13, 2024. Ms. Hirano's 10b5-1 Plan provides for the potential sale of up to 124,026 shares of our common stock, and expires on September 13, 2025, or upon the earlier completion of all authorized transactions thereunder. The first trade will not occur until January 2, 2025, at the earliest.

Kristen Yen, our Senior Vice President, Clinical Operations, adopted a 10b5-1 Plan on September 13, 2024. Ms. Yen's 10b5-1 Plan provides for the potential sale of up to 95,089 shares of our common stock, and expires on September 30, 2025, or upon the earlier completion of all authorized transactions thereunder. The first trade will not occur until January 2, 2025, at the earliest.

These trading arrangements are intended to satisfy the affirmative defense of Rule 10b5-1(c). Certain of our Section 16 Directors or Officers may participate in employee stock purchase plans, 401(k) plans or dividend investment plans of us that have been designed to comply with Rule 10b5-1(c). No non-Rule 10b5-1 trading arrangements (as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934) were adopted by any Section 16 Director or Officer during the third quarter of 2024. Additionally, no Rule 10b5-1 or non-Rule 10b5-1 trading arrangements were terminated by any Section 16 Director or Officer in the third quarter of 2024.
Non-Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Terminated false
Anish Bhatnagar [Member]  
Trading Arrangements, by Individual  
Name Anish Bhatnagar
Title Chief Executive Officer, President and Chief Operating Officer, and a member of our board of directors
Rule 10b5-1 Arrangement Adopted true
Adoption Date September 6, 2024
Expiration Date September 6, 2025
Arrangement Duration 365 days
Aggregate Available 300,000
Jim Mackaness [Member]  
Trading Arrangements, by Individual  
Name Jim Mackaness
Title Chief Financial Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date September 6, 2024
Expiration Date September 6, 2025
Arrangement Duration 365 days
Aggregate Available 60,000
Patricia C. Hirano [Member]  
Trading Arrangements, by Individual  
Name Patricia C. Hirano
Title Senior Vice President
Rule 10b5-1 Arrangement Adopted true
Adoption Date September 13, 2024
Expiration Date September 13, 2025
Arrangement Duration 365 days
Aggregate Available 124,026
Kristen Yen [Member]  
Trading Arrangements, by Individual  
Name Kristen Yen
Title Senior Vice President
Rule 10b5-1 Arrangement Adopted true
Adoption Date September 13, 2024
Expiration Date September 30, 2025
Arrangement Duration 365 days
Aggregate Available 95,089